Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices— After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints --Zuckerberg cash helping to propel Chicago's biotech ambitions -- See more on our front page news